Multiple Sclerosis Clinical Trial
Official title:
Long-term Surveillance of Patients With Multiple Sclerosis to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections Among Patients Treated With Natalizumab
The primary objective of the study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) and serious adverse events (SAEs) of other opportunistic infections (OIs) among all participants taking natalizumab. The secondary objectives of the study are to estimate the incidence of SAEs, to estimate the incidence of SAEs among participant subgroups defined by demographic and clinical factors (age, gender, duration of treatment, pregnancy, breastfeeding), to characterize and estimate incidences of malignancies, hypersensitivity reactions and John Cunningham Virus (JCV) positivity among all participants taking natalizumab, and to count and describe pregnancies and breastfeeding among participants previously exposed to natalizumab.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Key Inclusion Criteria: - Participants starting with natalizumab after 1st January 2019 and participating in the ReMuS will be included in this study Key Exclusion Criteria: - Not Applicable (NA) NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Czechia | Fakultní nemocnice Brno | Brno | |
Czechia | Fakultní nemocnice u sv. Anny v Brne | Brno | |
Czechia | Nemocnice Ceské Budejovice | Ceské Budejovice | |
Czechia | Fakultní nemocnice Hradec Králové | Hradec Králové | |
Czechia | Nemocnice Jihlava | Jihlava | |
Czechia | Fakultní nemocnice Olomouc | Olomouc | |
Czechia | Fakultní nemocnice v Ostrave | Ostrava | |
Czechia | Nemocnice Pardubického kraje | Pardubice | |
Czechia | Fakultní nemocnice v Plzni | Pilsen | |
Czechia | Fakultní nemocnice Královské Vinohrady v Praze | Prague | |
Czechia | Fakultní nemocniceMotol v Praze | Prague | |
Czechia | Fakultní Thomayerova nemocnice v Praze v Krci | Prague | |
Czechia | VÅ¡eobecná fakultní nemocnice v Praze | Prague | |
Czechia | Nemocnice Teplice | Teplice | |
Czechia | Krajská nemocnice T. Bati ve Zlíne | Zlín |
Lead Sponsor | Collaborator |
---|---|
Biogen | Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Progressive Multifocal Leukoencephalopathy (PML) who are Taking Natalizumab | Up to 6 years | ||
Primary | Number of Participants with Serious Adverse Events (SAEs) of Other Opportunistic Infections (OIs) who are Taking Natalizumab | SAE means such adverse event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a congenital anomaly or birth defect in offspring, irrespective of the administered dose of the medicinal product. Serious OI means such OI which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a birth defect in offspring. | Up to 6 years | |
Secondary | Number of Participants With SAEs | SAE means such adverse event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a congenital anomaly or birth defect in offspring, irrespective of the administered dose of the medicinal product. | Up to 6 years | |
Secondary | Number of Participants With SAEs Among Participant Subgroups Defined by Demographic and Clinical Factors | SAE means such adverse event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in permanent or significant damage to health or limitation of capabilities or is manifested as a congenital anomaly or birth defect in offspring, irrespective of the administered dose of the medicinal product. Demographic and clinical factors involve age, gender, duration of treatment, pregnancy, breastfeeding. | Up to 6 years | |
Secondary | Number of Participants With Malignancies who are Taking Natalizumab | Up to 6 years | ||
Secondary | Number of Participants With Hypersensitivity Reactions who are Taking Natalizumab | Up to 6 years | ||
Secondary | Number of Participants who are John Cunningham Virus (JCV) Positive and Taking Natalizumab | Up to 6 years | ||
Secondary | Number of Pregnant and Breastfeeding Participants who Were Previously Exposed to Natalizumab | Up to 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |